Pre-emptive therapy in the 2 randomization arms of the whole transplant patient population, and the 2 subgroups of HSCT recipients from UD and sibling
. | Total patient population in the randomization arm . | . | . | HSCT from UD in the randomization arm . | . | . | HSCT from siblings in the randomization arm . | . | . | |||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| . | IEmRNA . | Antigenemia . | . | IEmRNA . | Antigenemia . | . | IEmRNA . | Antigenemia . | . | |||
| Parameter . | n = 41 . | n = 39 . | P . | n = 18 . | n = 17 . | P . | n = 23 . | n = 22 . | P . | |||
| No. (%) of patients | ||||||||||||
| HCMV-infected (first episode) | 33 (80.5) | 20 (51.3) | .006* | 15 (83.3) | 6 (35.3) | .006† | 18 (78.3) | 14 (63.7) | NS* | |||
| Treated | 27 (65.9) | 17 (43.6) | .045* | 15 (83.3) | 6 (35.3) | .006† | 12 (52.2) | 11 (50.0) | NS* | |||
| Duration of therapy‡ | 12 (5-45) | 13 (6-28) | NS§ | 13 (6-35) | 15.5 (6-28) | NS§ | 11 (5-45) | 13 (6-20) | NS§ | |||
| No. (%) of relapsing patients: | ||||||||||||
| Detected | 21 of 27 (80.0) | 10 of 17 (58.8) | NS* | 11 of 15 (73.3) | 4 of 6 (66.7) | NS† | 10 of 12 (83.3) | 5 of 11 (45.5) | .089† | |||
| Treated | 16 of 21 (76.2) | 7 of 10 (70.0) | NS† | 10 of 11 (90.9) | 3 of 4 (75.0) | NS† | 6 of 10 (60.0) | 3 of 5 (60.0) | NS† | |||
| Duration of therapy‡ | 16 (6-46) | 16 (7-48) | NS§ | 20.5 (6-46) | 19.5 (13-48) | NS§ | 9.5 (7-17) | 13 (7-16) | NS§ | |||
| Overall duration of therapy‡∥ | 25 (5-68) | 19 (9-76) | NS§ | 30 (7-68) | 25.5 (9-76) | NS§ | 15.5 (5-62) | 17 (9-26) | NS§ | |||
| No. of patients with HCMW disease | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
. | Total patient population in the randomization arm . | . | . | HSCT from UD in the randomization arm . | . | . | HSCT from siblings in the randomization arm . | . | . | |||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| . | IEmRNA . | Antigenemia . | . | IEmRNA . | Antigenemia . | . | IEmRNA . | Antigenemia . | . | |||
| Parameter . | n = 41 . | n = 39 . | P . | n = 18 . | n = 17 . | P . | n = 23 . | n = 22 . | P . | |||
| No. (%) of patients | ||||||||||||
| HCMV-infected (first episode) | 33 (80.5) | 20 (51.3) | .006* | 15 (83.3) | 6 (35.3) | .006† | 18 (78.3) | 14 (63.7) | NS* | |||
| Treated | 27 (65.9) | 17 (43.6) | .045* | 15 (83.3) | 6 (35.3) | .006† | 12 (52.2) | 11 (50.0) | NS* | |||
| Duration of therapy‡ | 12 (5-45) | 13 (6-28) | NS§ | 13 (6-35) | 15.5 (6-28) | NS§ | 11 (5-45) | 13 (6-20) | NS§ | |||
| No. (%) of relapsing patients: | ||||||||||||
| Detected | 21 of 27 (80.0) | 10 of 17 (58.8) | NS* | 11 of 15 (73.3) | 4 of 6 (66.7) | NS† | 10 of 12 (83.3) | 5 of 11 (45.5) | .089† | |||
| Treated | 16 of 21 (76.2) | 7 of 10 (70.0) | NS† | 10 of 11 (90.9) | 3 of 4 (75.0) | NS† | 6 of 10 (60.0) | 3 of 5 (60.0) | NS† | |||
| Duration of therapy‡ | 16 (6-46) | 16 (7-48) | NS§ | 20.5 (6-46) | 19.5 (13-48) | NS§ | 9.5 (7-17) | 13 (7-16) | NS§ | |||
| Overall duration of therapy‡∥ | 25 (5-68) | 19 (9-76) | NS§ | 30 (7-68) | 25.5 (9-76) | NS§ | 15.5 (5-62) | 17 (9-26) | NS§ | |||
| No. of patients with HCMW disease | 0 | 0 | 0 | 0 | 0 | 0 | ||||||